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ORIGINAL RESEARCH
Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t 
eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and 
enhances antigen cross-presentation
Mark A. J. M. Hendriksa, Emily M. Ploeg a, Iris Koopmansa, Isabel Britsch a, Xiurong Kea,b, Douwe F. Samploniusa, 
and Wijnand Helfricha
aDepartment of Surgery, Laboratory for Translational Surgical Oncology, University of Groningen, University Medical Center Groningen (UMCG), 
Groningen, The Netherlands; bDepartment of Immunotherapy and Gastrointestinal Oncology, Affiliated Cancer Hospital of Shantou University Medical 
College, Shantou, China
ABSTRACT
Cancer cells overexpress CD47 to subvert phagocytic elimination and evade immunogenic processing of 
cancer antigens. Moreover, CD47 overexpression inhibits the antibody-dependent cellular phagocytosis 
(ADCP) and cytotoxicity (ADCC) activities of therapeutic anticancer antibodies. Consequently, CD47- 
blocking antibodies have been developed to overcome the immunoevasive activities of cancer cell- 
expressed CD47. However, the wide-spread expression of CD47 on normal cells forms a massive “antigen 
sink” that potentially limits sufficient tumor accretion of these antibodies. Additionally, a generalized 
blockade of CD47-SIRPα interaction may ultimately lead to unintended cross-presentation of self-antigens 
potentially promoting autoimmunity. To address these issues, we constructed a bispecific antibody, 
designated bsAb CD47xEGFR-IgG1, that blocks cancer cell surface-expressed CD47 in an EGFR-directed 
manner. BsAb CD47xEGFR-IgG1 selectively induced phagocytic removal of EGFRpos/CD47pos cancer cells 
and endowed neutrophils with capacity to kill these cancer cells by trogoptosis; an alternate form of ADCC 
that disrupts the target cell membrane. Importantly, bsAb CD47xEGFR-IgG1 selectively enhanced phago-
cytosis and immunogenic processing of EGFRpos/CD47pos cancers cells ectopically expressing viral protein 
CMVpp65.
In conclusion, bsAb CD47xEGFR-IgG1 may be useful to reduce on-target/off-tumor effects of CD47- 
blocking approaches, enhance cancer cell elimination by trogoptosis, and promote adaptive anticancer 
immune responses.
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CD47 is a multifunctional pentaspanin transmembrane glyco-
protein that is expressed on virtually all normal cell types. One 
of its most prominent functions involves interaction with sig-
nal regulatory protein alpha (SIRPα), a cell surface glycopro-
tein expressed by various types of phagocytes (reviewed in1). 
CD47-SIRPα interaction leads to phosphorylation of the ITIM 
motif of SIRPα which subsequently initiates a signal transduc-
tion cascade that result in the inhibition of the phagocytic 
activity of, e.g. macrophages and dendritic cells (DCs).2 In 
this respect, CD47-SIRPα interaction has been hailed as 
a “Don’t eat me” immune checkpoint that serves to prevent 
the untimely phagocytic removal of normal healthy cells. 
Unfortunately, a broad variety of hematologic and solid malig-
nancies appear to misuse the CD47-SIRPα immune checkpoint 
by overexpressing CD47, thereby evading phagocytic elimina-
tion and subsequent immunogenic processing of 
neoantigens.3–5 Moreover, CD47 overexpression by cancer 
cells was shown to reduce the efficacy of therapeutic anticancer 
antibodies by inhibiting their capacity to induce antibody- 
dependent cellular cytotoxicity (ADCC) and antibody depen-
dent cellular phagocytosis (ADCP).6
Previously, it was demonstrated that CD47-blocking anti-
bodies can be exploited to restore phagocytic elimination of 
CD47-overexpressing cancer cells and subsequent promote 
adaptive immunity toward these cancer cells.5,7 Moreover, 
CD47-blocking antibodies enhanced ADCP and ADCC- 
mediated anticancer activity of rituximab and 
trastuzumab.6,8,9 Currently, several CD47-blocking antibodies 
are being evaluated in clinical trials, alone or in combination 
with therapeutic anticancer antibodies (ClinicalTrials.gov 
identifier: NCT02953509, NCT02953782, and NCT03558139).
However, the clinical efficacy of current CD47-blocking 
antibodies is anticipated to be hampered by the wide-spread 
expression of CD47 on normal cells which may limit sufficient 
antibody accretion at the tumor site(s).10–13 Moreover, the lack 
of cancer selectivity of current monospecific CD47-blocking 
antibodies may result in a generalized blockade of CD47 pre-
sent on normal cells which in turn may promote cross- 
presentation of self-antigens, thereby increasing the risk of 
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breaking self-tolerance and inducing unpredictable immune- 
related adverse events.
In this respect, a bispecific antibody-based approach may be 
a suitable strategy to block the CD47-SIRPα immune check-
point in a more tumor-restricted manner. Bispecific antibodies 
(bsAbs) can be designed to combine two independent target 
functionalities into one antibody-based therapeutic molecule. 
Moreover, bsAbs can be readily equipped with an Fc-domain 
Ig isotype of choice engineered to have natural, enhanced, 
reduced or even nullified effector activity.
The epidermal growth factor receptor (EGFR) appears to be 
particularly suitable tumor target for a bsAb-based approach 
for blocking CD47 in a more tumor-directed manner. EGFR is 
overexpressed and/or mutated in broad variety of malignancies 
and is an established target for therapeutic antibodies to selec-
tively bind to cancer cells and inhibit EGFR-mediated onco-
genic signaling.14–16
Here, we present a novel bispecific antibody (bsAb), desig-
nated CD47xEGFR-IgG1, that directs CD47-blockade toward 
EGFR-overexpressing cancer cells. BsAb CD47xEGFR-IgG1 
has dual binding capacity for both EGFR and CD47, antago-
nizes their respective oncogenic activities, and is equipped with 
a fully functional human IgG1 Fc effector domain. Our data 
demonstrates that bsAb CD47xEGFR-IgG1 has multiple 
mutually reinforcing anticancer activities that are not available 
in any of the currently available conventional CD47-blocking 
antibodies and as such may be useful to reduce on-target/off- 
tumor effects, enhance cancer cell elimination by ADCC, and 
promote adaptive anticancer immune responses.
Materials and methods
Antibodies and reagents
The following primary fluorescently-labeled murine mAbs 
directed against human antigens were used: FITC/APC- 
labeled CD47-blocking antibody B6H12 (eBioscience), FITC- 
labeled nonblocking anti-CD47 antibody 2D3 (eBioscience), 
FITC/APC-labeled anti-EGFR (clone 528, Santa Cruz), PerCP- 
Cy5.5-labeled anti-CD3 (clone OKT-3, eBioscience), PE- 
labeled anti-CD137 (clone 4B4-1, BD Pharmingen), APC- 
labeled anti-CD8 (clone RPA-T8, eBioscience). Fluorescently 
labeled secondary antibody goat anti-human Ig PE was from 
Southern Biotech. Unconjugated antibodies used: CD47- 
blocking mAb B6H12 (Thermofisher), anti-EGFR mAb 425 
(Merck), and HLA-ABC-blocking mAb W6/32 
(Immunotools).
The following reagents were used: Annexin-V-FITC 
(Immunotools), propidium iodide (PI) (Invitrogen), and 
Vybrant DiD, DiO, CFSE, CellTrace Far Red cell proliferation 
kits (Thermofisher). Secretion of IFNγ was measured using 
appropriate ELISA kit (eBioscience).
Cell lines
Cell lines A2058, A375m, A431, FaDu, NCI-H292, K562, 
OvCAR3, DLD1, SJSA1, Pea1, SKOV3, BJAB, PR1, 
HEK293T, and CHO-K1 cells were obtained from the 
American Type Culture Collection (ATCC). Cells were 
cultured in RPMI-1640 or DMEM (Lonza) as indicated, sup-
plemented with 10% fetal calf serum (FCS, Thermo Scientific) 
at 37°C in a humidified 5% CO2 atmosphere. CHO-K1 cells 
were cultured in GMEM (First Link), supplemented with 5% 
dialyzed FBS (Sigma Aldrich). CHO.CD47, CHO.EGFR and 
K562.EGFR cells stably expressing human CD47 or EGFR were 
generated by lipofection (Fugene-HD, Promega) of plasmid 
pCMV6-AC-GFP or plasmid pCMV3-C-GFPSpark, contain-
ing cDNAs encoding human CD47 (Origene) or human EGFR 
(Sino Biological), respectively.
Isolation of neutrophils and macrophages
Neutrophils were isolated from heparinized blood from 
healthy volunteers after informed consent by density gradient 
centrifugation followed by selective removal of remaining ery-
throcytes using ammonium chloride-mediated lysis method. 
Peripheral blood mononuclear cells (PBMCs) were obtained by 
density gradient centrifugation (Lymphoprep, Stemcell tech-
nologies). Monocytes were isolated from PBMCs using anti- 
CD14-coated magnetic beads (Miltenyi Biotec) and MACS. For 
generation of M0 macrophages, monocytes (2 × 105 cells/ml) 
were cultured in RPMI-1640/10% FCS, supplemented with 
50 ng/ml GM-CSF (Immunotools) for 6 d. Macrophages were 
polarized toward the M1 phenotype by incubation in medium 
containing 20 ng/ml IFNγ (Immunotools) and 50 ng/ml LPS 
(Sigma Aldrich) for 24 h.
Lentiviral transduction of CMVpp65 expression in cancer 
cells
OvCAR3 and K562 cells were transduced using CMVpp65- 
encoding recombinant lentiviral particles (a kind gift from 
Dr. Renata Stripecke, Hannover Medical School, Germany) 
according to standard procedures. Ectopical expression of 
CMVpp65 in transduced cell lines was evaluated after 48 h by 
immunocytochemistry using an anti-CMVpp65 antibody 
cocktail (IQ Products) and an HRP-conjugated rabbit anti- 
mouse antibody (Dako).
CD47 knock-out (KO) A431 and FaDu cancer cells lines 
were generated by transfection with pSpCas9 BB-2A-GFP 
(PX458) plasmid (Origene) encoding sgRNA 5ʹ- 
ATCGAGCTAAAATATCGTGT-3ʹ17 and subsequent single- 
cell sorting at the UMCG Flow Cytometry facility.
Construction of bsAb CD47xEGFR-IgG
DNA fragments encoding scFv MABL and scFv 425 were 
generated by commercial gene synthesis service (Genscript) 
based on published VH and VL sequence data.18,19 For con-
struction and production of bsAb CD47xEGFR-IgG, we used 
eukaryotic expression plasmid pEE14-bsAb, which contains 3 
consecutive multiple cloning sites (MCS). MCS#1 and MCS#2 
are interspersed by a 22 amino acid flexible linker.20 MCS#1, 
MCS#2 were used for directional and in-frame insertion of 
DNA fragments encoding scFv MABL, scFv 425, and MCS#3 
for insertion of DNA fragments encoding human Fc IgG1, 
IgG2s21 or IgG4, respectively (Figure S1a,b). Analogously, 
pEE14-CD47xMock-IgG1 encoding bsAb CD47xMock-IgG1 
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was constructed by replacing scFv425 in pEE14-CD47xEGFR- 
IgG1 by scFv4-4-20 directed against fluorescein.22
Production of recombinant bsAbs
BsAbs CD47xEGFR-IgG1, -IgG2s, -IgG4, and appropriate 
mock control bsAbs were produced using the Expi293 expres-
sion system (Thermo Fisher Scientific). Briefly, Expi293 cells 
were transfected with pEE14-bsAb plasmid encoding the 
desired bsAb and subsequently cultured on a shaker platform 
(125 rpm) at 37°C, 8% CO2 for 7 d. Conditioned culture super-
natant was harvested and cleared by centrifugation (3000 × g, 
30 min), after which bsAbs were purified using an HiTrap 
protein A HP column connected to an ÄKTA Start chromato-
graphy system (GE Healthcare Life Sciences).
Assessment of dual binding activity of bsAb 
CD47xEGFR-IgG1
Dual binding activity of bsAb CD47xEGFR-IgG1 for EGFR 
and CD47 was assessed by flow cytometry using CHO.EGFR 
or CHO.CD47 cells versus parental CHO cells. In short, cells 
were incubated with increasing amounts of bsAb 
CD47xEGFR-IgG1 (0.01–10 µg/ml) at 4°C for 45 min after 
which binding was evaluated using a PE-labeled anti-human- 
Ig-antibody. Similarly, binding of bsAbs CD47xEGFR-IgG1 
and CD47xMock-IgG1 to EGFR was assessed using a panel of 
EGFRposCD47pos and EGFRnegCD47pos cancer cell lines.
The capacity of bsAb CD47xEGFR-IgG1 to simultaneously 
bind to EGFR on one cell type and CD47 on a proximal other 
cell type was assessed by flow cytometry. In short, EGFRpos 
A431.CD47KO cancer cells (DiD-labeled) and CHO.CD47 
(CSFE-labeled) were incubated with bsAb CD47xEGFR-IgG1 
(1 µg/ml at 4°C for 45 min) in the presence (or not) of excess 
amounts (10 µg/ml) of CD47-blocking mAb B6H12 or anti- 
EGFR mAb 425. The amount of DiDpos/CFSEpos cell clusters 
was evaluated by flow cytometry.
Competitive binding assay
The overall binding strength (avidity) of bsAbs CD47xEGFR- 
IgG1 and CD47xMock-IgG1 for EGFRposCD47pos cancer cells 
was compared in a competitive binding assay.23 In short, A431 
cells were incubated with an APC-labeled CD47-blocking mAb 
(4°C for 10 min), after which bsAb CD47xEGFR-IgG1 or 
CD47xMock-IgG1 was added in a concentration range from 
0.01 to 10 μg/ml. After 45 min of incubation, residual binding 
of APC-labeled CD47-blocking antibody was quantified by 
flow cytometry. Where indicated, A431 cells were pre- 
incubated with excess amounts of mAb 425 (10 μg/ml) at 4°C 
for 45 min prior to addition of bsAbs.
Inhibition of EGFR-mediated cell proliferation by bsAb 
CD47xEGFR-IgG1
NCI-H292 cells (8 × 103/well) were seeded into an E-plate 16 
(ACEA Biosciences) and treated in the continuous presence of 
bsAb CD47xEGFR-IgG1 or control bsAbs (2 μg/ml) at 37°C. 
Cell proliferation was monitored for 96 h using the 
xCELLigence RTCA instrument (ACEA Biosciences). Graphs 
show mean ± SD from duplicates.
Assessment of internalization by bsAb CD47xEGFR-IgG1
Internalization of antibody/antigen complexes was assessed by 
incubating EGFRpos/CD47pos NCI-H292 cells with bsAb 
CD47xEGFR-IgG1 or control bsAbs (2 μg/ml) in the presence 
of anti-human Fc saporin-6 toxin-labeled Fab (Fab-ZAP, 
Advanced Targeting Systems). After 72 h, apoptotic cancer 
cell death was evaluated by flow cytometry using annexinV/ 
PI staining.
The capacity of bsAb CD47xEGFR-IgG1 to internalize 
EGFR and CD47 upon binding was assessed using a panel of 
solid cancer cell types by flow cytometry. In short, cancer cells 
were treated with bsAb CD47xEGFR-IgG1 (1 μg/ml) or appro-
priate controls at 37°C for 24 h, after which residual EGFR and 
CD47 cell surface exposure was assessed using anti-EGFR mAb 
528 and anti-CD47 mAb 2D3. Of note, mAb 528 and mAb 2D3 
bind to nonoverlapping epitopes on EGFR and CD47, respec-
tively and do not interfere with the EGFR and/or CD47- 
binding by bsAb CD47xEGFR-IgG1.
Confocal microscopy
NCI-H292 cancer cells were seeded on PET-coated chamber 
slides and treated with bsAb CD47xEGFR-IgG1 (2 μg/ml) or 
appropriate controls at 37°C. After 24 h, cells were fixed in 4% 
PFA and stored in PBS at 4°C until further use. After blocking 
with 1% BSA (Sigma-Aldrich) for 30 minutes, the slides were 
incubated overnight with CD47 primary polyclonal antibody 
(AF4670, R&D Systems) and EGFR primary antibody (clone 
D38B1, Cell Signaling Technologies) at 4°C. Next, slides were 
stained for 1.5 h at RT with DxR 555 (1:5000 dilution, Abcam) 
and DxS 647 (1:250 dilution, Abcam) secondary antibodies and 
mounted with prolong Gold antifade with DAPI 
(Thermofisher). Confocal microscopy images were taken with 
the Confocal TCS SP8 (Leica) at the UMCG Microscopy and 
Imaging Center.
Assessment of bsAb-mediated ADCC
The capacity of bsAb CD47xEGFR-IgG1 and appropriate (iso-
type) control bsAbs to induce ADCC upon opsonizing cancer 
cells was assessed using an ADCC bioluminescent reporter 
bioassay (Promega). This assay exploits Jurkat T cells engi-
neered to express FcγRIIIa. Binding of the Fc region of 
a bsAb to this FcγRIIIa activates luciferase gene transcription 
through the NFAT pathway. In short, EGFRpos FaDu cells and 
EGFRneg A375m cells (2 × 104) were seeded in a 96-wells plate 
and cultured for 18 h. Subsequently, Jurkat.FcγRIIIa-NFAT- 
luciferase cells were added at an E:T cell ratio of 1:1 and then 
treated for 6 h with bsAb CD47xEGFR-IgG1, -IgG2s, or -IgG4 
Fc isotype variants or CD47xMock-IgG1 (all antibodies were 
added in 0,1 µg/ml final concentration), respectively, after 
which luciferase activity (RLU) was measured using a Victor 
V3 multilabel plate reader (Perkin Elmer). Additionally, the 
capacity of bsAb CD47xEGFR-IgG1 and bsAb CD47xEGFR- 
IgG2s to induce ADCC was assessed in a PBMC-based ADCC 
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assay. In short, freshly-isolated PBMCs were cocultured with 
DiD-labeled A431 cancer target cells at an E:T cell ratio of 5:1 
for 24 h in the presence (or absence) of bsAb CD47xEGFR- 
IgG1 or CD47xEGFR-IgG2s (both 2 µg/ml). Induction of 
apoptotic cancer cell death (annexin Vpos/PIpos) was assessed 
by flow cytometry.
Assessment of antibody-mediated trogocytosis
Antibody-dependent trogocytic uptake of cancer cell mem-
brane parts by human neutrophils was quantified by flow 
cytometry. In short, cancer cells were labeled with lipophilic 
membrane dye DiD according to manufacturer’s protocol and 
cocultured at an E:T cell ratio of 1:1 with purified neutrophils 
in the presence of CD47xEGFR-IgG1 (1 μg/ml) or appropriate 
controls for 2 h. Neutrophils were gated based on their FSC/ 
SSC characteristics after which the percentage of DiDpos neu-
trophils was evaluated. The flow cytometry gating strategy used 
for assessment of neutrophil trogocytosis was as previously 
described by us.19 Kinetics of the trogocytosis process were 
evaluated as follows; cocultures of DiDpos cancer cells and 
neutrophils (E:T cell ratio of 5:1) were treated with cetuximab 
(Merck KGaA) (1 μg/ml), bsAb CD47xEGFR-IgG2s (1 μg/ml) 
or anti-EpCAM-IgG124 (2 μg/ml), respectively and incubated 
at 37°C for 0, 10, 20, 40, 60, or 90 min.
Assessment of antibody-mediated trogoptosis
Next, we evaluated whether trogocytosis of cancer cells by 
neutrophils was followed by apoptotic cell death, hereafter 
indicated as trogoptosis as recently described in.25 In short, 
FaDu cells and FaDu.CD47KO (1.5 × 104/well) were seeded 
into an E-plate 16 and allowed to adhere for 24–48 h, after 
which neutrophils were added (E:T cell ratio of 10:1). 
Cocultures were treated with bsAb CD47xEGFR-IgG1, -IgG4 
or -IgG2s (2 μg/ml) or anti-EpCAM-IgG1 (2 μg/ml), respec-
tively. Induction of trogoptosis was monitored for up to 48 h of 
treatment using the xCELLigence RTCA instrument. Cell 
index was normalized prior to addition of neutrophils and 
antibodies. Graphs show mean ± SD from quadruplicates.
M1 macrophage phagocytosis assay
CellTrace Far Red-labeled M1 macrophages were coincubated 
with CFSE-labeled or GFP-labeled cancer cells (E:T cell ratio of 
1:2) in the presence of bsAb CD47xEGFR-IgG1 (1 μg/ml) or 
appropriate control bsAbs at 37°C for 3 h. The capacity of M1 
macrophages for ADCP of antibody-opsonized cancer cells 
was evaluated by flow cytometry and was indicated as the 
percentage of CFSEpos macrophages within the population of 
Far Redpos macrophages.
Generation and expansion of CMVpp65-specific CD8pos 
T cells
Peripheral blood lymphocytes (PBLs) were freshly isolated 
from PBMCs from an HLA-B*0702 CMV-positive healthy 
volunteer and depleted of monocytes using anti-CD14-coated 
magnetic beads. Subsequently, the PBLs (5 × 106/ml) were 
cultured in a 6-wells plate using X-VIVO15 medium (Lonza) 
and stimulated by adding 5–10 μl of a commercial recombinant 
CMVpp65 protein solution (Miltenyi Biotech) per ml of cell 
suspension and then cultured for 2–3 d. Next, CMVpp65- 
stimulated PBLs were harvested and resuspended in fresh 
X-VIVO15 medium supplemented with 500–1000 U/ml IL-2 
(Immunotools) and cultured for 2–4 additional days. 
Subsequently, CMVpp65-stimulated PBLs were cultured on 
a feeder layer of OvCAR3.pp65 cells (HLA-B*0702pos) in 
X vivo 15 medium at an E:T cell ratio of 7.5:1 for 24 h. Next, 
CMVpp65-restimulated PBLs were harvested, washed and 
resuspended in X-VIVO15 medium supplemented with IL-2 
and cultured for 2–4 d. Flow cytometry indicated that this 
stimulation protocol yielded >60% CMVpp65-dextramerepos 
(HLA-B*0702/TPRVTGGGAM-APC, Immudex) CD8pos 
T cells (Figure S5). After up to 7 stimulation rounds, 
CMVpp65-specific CD8pos T cells were frozen until used.
Assessment of antigen-specific T cell activation in a 
CMVpp65-based model system
M1 macrophages were seeded in a flat-bottom 96 wells plate 
(4 × 104 cells/well) using macrophage attachment medium 
(Promocell) and cocultured with K562.EGFR.pp65 cells (E:T 
cell ratio of 1:2) in the presence of bsAbs (1 μg/ml) at 37°C for 
3 h. Next, K562.EGFR.pp65 cells were removed after which 
autologous CMVpp65-specific CD8pos T cells (see above) were 
added (E:T cell ratio of 1:1) in the presence or absence of HLA 
ABC-blocking antibodies (10 μg/ml) for 24 h. The percentage 
of CD137pos T cells relative to CD3pos/CD8pos T cells was 
evaluated by flow cytometry. The spend culture media were 
evaluated for the amount of T cell-secreted IFNγ by ELISA.
Results
bsAb CD47xEGFR-IgG1 simultaneously binds to CD47 and 
EGFR
BsAb CD47xEGFR-IgG1 dose-dependently bound to CHO. 
EGFR cells and not to CHO cells (Figure 1a) and binding 
positively correlated with the respective EGFR-expression 
levels of the various EGFRpos cancer cell lines evaluated 
(Figure S2a,b). Similarly, bsAb CD47xEGFR-IgG1 bound to 
CHO.CD47 cells and not to parental CHO cells (Figure 1b). 
Importantly, bsAb CD47xEGFR-IgG1 showed enhanced bind-
ing toward EGFRpos/CD47pos cancer cells due to the enhanced 
avidity effect of its dual binding capacity for both EGFR and 
CD47 (Figure 1c). Of note, bsAb CD47xEGFR-IgG1 has 
a ~ 4.5-fold higher binding capacity for K562.EGFR cells com-
pared with K562 cells. K562 and K562.EGFR have similar 
CD47 expression levels; therefore, the difference in binding 
capacity is likely due to enhanced avidity effect of simulta-
neously binding to CD47 and EGFR (Figure S2c,d).
Additionally, bsAb CD47xEGFR-IgG1 was able to simulta-
neously bind to EGFR present on one cell type and CD47 on 
other cell type present in close proximity. In particular, bsAb 
CD47xEGFR-IgG1 simultaneously bound to and cellularly 
bridged A431.CD47KO cancer cells (DiD-labeled) and CHO. 
CD47 cells (CSFE-labeled) as was evident from a marked 
4 M. A. J. M. HENDRIKS ET AL.
increase in DiDpos/CFSEpos cell clusters detected by flow cyto-
metry. Of note, DiDpos/CFSEpos cell cluster formation was 
strongly reduced in the presence of excess amounts of either 
CD47-blocking mAb B6H12 or EGFR-blocking mAb 425 
(Figure 1d).
bsAb CD47xEGFR-IgG1 blocks CD47 in an EGFR-directed 
manner
BsAb CD47xEGFR-IgG1 and bsAb CD47xMock-IgG1 were 
compared for their capacity to block CD47 on EGFR- 
expressing cancer cells using a competitive binding assay.23 
In this assay, displacement of an APC-labeled CD47-blocking 
mAb bound to EGFRpos/CD47pos A431 cancer cells was eval-
uated in the competing presence of bsAb CD47xEGFR-IgG1. 
The IC50 of bsAb CD47xEGFR-IgG1 for displacing APC- 
labeled CD47-blocking mAb from A431 cells was calculated 
to be 0.14 μg/ml, which is ~8.4 times lower than that of bsAb 
CD47xMock-IgG1 (1.20 μg/ml) (Figure 1e). Importantly, pre- 
incubation with an excess amount of EGFR-blocking mAb 425 
essentially abrogated the capacity of bsAb CD47xEGFR-IgG1 
to displace APC-labeled CD47-blocking mAb (Figure 1f). 
Figure 1. BsAb CD47xEGFR-IgG1 selectively and simultaneously binds to EGFR and CD47. Dose-dependent binding of CD47xEGFR-IgG1 to (a) CHO.EGFR or (b) CHO.CD47 
cells vs. parental CHO cells. (c) Binding of CD47xEGFR-IgG1 or CD47xMock-IgG1 (1 µg/ml) to a panel of EGFRpos and EGFRneg CD47-expressing cell lines. (d) Binding of 
CD47xEGFR-IgG1 (1 µg/ml) to (GFP-labeled) CHO.CD47 cells and (DiD-labeled) parental A431 or A431.CD47KO cells in the presence or absence of excess CD47-blocking 
antibody B6H12 and/or EGFR-blocking antibody mAb 425 (both 10 µg/ml). The percentage of DiD/GFP double positive events upon incubation with indicated 
antibodies is shown. (e) Competitive binding assay in which APC-conjugated CD47 antibody (B6H12) competed with increasing doses (0.01–10 µg/ml) of bsAb 
CD47xEGFR-IgG1 (white squares), CD47xMock-IgG1 (black triangles) or MockxMock-IgG1 (white dots) for binding to A431 cells. (f) Competitive binding assay, as in E, in 
which A431 cells were pretreated with excess amounts of mAb 425 or isotype control IgG2a (both 10 µg/ml) prior to addition of CD47xEGFR-IgG1 (1 µg/ml), where 
indicated. (g) In vitro binding of CD47xEGFR-IgG1 and B6H12-hIgG1 to RBC present in whole blood. (h) Binding assay of CD47xEGFR-IgG1 (20 µg/ml) to DiO-labeled NCI- 
H292 cancer cells in the presence of increasing concentrations of whole blood. Of note, RBC in whole blood form an abundant “antigen-sink” for CD47-antibodies. All 
binding experiments were analyzed by flow cytometry. All graphs represent mean ± SD. Statistical analysis in F was performed using one-way ANOVA followed by 
a Tukey post-hoc test (*p < .05, **p < .01, ***p < .001, ****p < .0001, ns not significant).
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Additionally, in vitro binding (MFI) of CD47xEGFR-IgG1 to 
RBC present in whole blood was calculated to be ~8 times 
lower than B6H12-hIgG1 (Figure 1g). In an RBC competitive 
binding assay, binding of CD47xEGFR-IgG1 to DiO-labeled 
NCI-H292 cancer cells was largely preserved in the presence of 
increasing concentrations of whole blood (Figure 1h). Taken 
together, these data demonstrated that bsAb CD47xEGFR- 
IgG1 has strongly enhanced binding capacity toward 
EGFRpos/CD47pos cancer cells endowing it with capacity to 
block CD47 in an EGFR-directed manner.
bsAb CD47xEGFR-IgG1 inhibits cancer cell proliferation
In RTCA cell proliferation analysis, bsAb CD47xEGFR-IgG1 
showed a higher capacity to inhibit proliferation of EGFRpos/ 
CD47pos NCI-H292 cancer cells than bsAb CD47xMock-IgG1 
Figure 2. BsAb CD47xEGFR-IgG1 inhibits cancer cell proliferation and induces cointernalization of EGFR and CD47 from the cancer cell surface. (a) Cell proliferation of 
NCI-H292 cells was measured during 96 h of continuous treatment with bsAb CD47xEGFR-IgG1 or control antibodies (2 µg/ml) in an xCELLigence Real-Time Cell 
Proliferation assay. (b) FaDu cells were incubated with bsAb CD47xEGFR-IgG1 at 37°C and residual cell-surface presence of CD47 and EGFR were measured over time by 
flow cytometry and compared to medium control. Similar to B, residual cell-surface presence of CD47 (c) and EGFR (d) were measured on A431, NCI-H292, and FaDu cells 
after incubation with bsAb CD47xEGFR-IgG1 or control antibodies (1 µg/ml) at 37°C for 24 h. (e) Apoptosis of NCI-H292 cells upon internalization of EGFR and/or CD47 
by indicated antibodies in the presence of Fab-ZAP, a chemical conjugate of goat anti-human monovalent antibody and saporin, was measured after 72 h. Apoptosis 
was measured with annexinV-staining using flow cytometry and expressed as percentage increase compared to medium control. (f) Representative confocal images of 
NCI-H292 cells stained with DAPI, EGFR antibody and CD47 antibody after 24 h internalization with bsAb CD47xEGFR-IgG1 or control antibodies (2 µg/ml). All graphs 
represent mean ± SD. Error bars in graph (a) and (b) indicate SD of duplicates. Statistical analysis in (c–e) was performed using One-way ANOVA followed by a Tukey 
post-hoc test (*p < .05, **p < .01, ***p < .001, ****p < .0001, ns not significant).
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or MockxEGFR-IgG1. After continuous treatment for 4 d with 
bsAb CD47xEGFR-IgG1, the proliferation of NCI-H292 can-
cer cells (expressed as ”cell index”) was inhibited by 49% 
compared to that of NCI-H292 cells treated with MockxMock- 
IgG1. MockxEGFR-IgG1 and CD47xMock-IgG1 inhibited the 
cell index by 39% and 15%, respectively (Figure 2a).
bsAb CD47xEGFR-IgG1 induces cointernalization and 
subsequent prolonged displacement of both EGFR and 
CD47 from the cancer cell surface
Treatment of EGFRpos/CD47pos cancer cells with bsAb 
CD47xEGFR-IgG1 resulted in a prolonged displacement of 
EGFR and CD47 molecules from the cancer cell surface for 
48 h and 24 h, respectively (Figure 2b). After treatment of FaDu 
cancer cells with CD47xEGFR-IgG1 for 24 h, residual cell sur-
face presence of EGFR and CD47 dropped down to ~50% and 
~60%, respectively (Figure 2b–d). Moreover, a potent approxi-
mately twofold increase (p < .01) in saporin-mediated apopto-
tic cell death in NCI-H292 cancer cells was induced by 
´piggybacking´ of the Fab-ZAP toxin on internalizing bsAb 
CD47xEGFR-IgG1 molecules. When using bsAbs 
MockxEGFR-IgG1 or CD47xMock-IgG1 a lower increase in 
apoptosis was observed of ~60% (ns) or ~40% (p < .05), respec-
tively (Figure 2e). Additionally, confocal microscopy images of 
NCI-H292 cells treated with bsAb CD47xEGFR-IgG1 for 24 h, 
clearly show reduced CD47 and EGFR cell surface presence 
(Figure 2f). Taken together, these data demonstrated that bsAb 
CD47xEGFR-IgG1 strongly inhibits cancer cell proliferation 
and induces prolonged displacement of both EGFR and 
CD47 from the cancer cell surface.
bsAb CD47xEGFR-IgG1 has enhanced ADCC signaling 
capacity toward EGFRpos/CD47pos cancer cells
BsAb CD47xEGFR-IgG1 and the IgG4 and IgG2-silent isotype 
variants thereof were assessed for capacity to induce FcγIIIa 
(CD16)-mediated ADCC activity toward EGFRpos/CD47pos can-
cer cells using a Jurkat.FcγRIIIa-NFAT-luc ADCC bioassay. The 
ADCC-signaling capacity of bsAb CD47xEGFR-IgG1 toward 
EGFRpos/CD47pos cancer cells was twofold higher than that of 
bsAb CD47xMock-IgG1, whereas ADCC-signaling capacities 
toward EGFRneg/CD47pos cancer cells were essentially identical 
(Figure 3a). As expected, bsAbs CD47xEGFR-IgG4 and 
CD47xEGFR-IgG2s were devoid of ADCC-signaling activity. 
Moreover, bsAb CD47xEGFR-IgG1, but not bsAb CD47xEGFR- 
IgG2s, engaged the ADCC activity of PBMCs (5 out of 5 donors) 
immune effector cells toward A431 cancer target cells in 
a PBMC-based ADCC assay (Figure 3b). Of note, bsAbs 
CD47xEGFR-IgG1, IgG4, and IgG2s showed equal binding 
activity toward EGFRpos/CD47pos cancer cells (Figure S2e).
bsAb CD47xEGFR-IgG1 potentiates trogocytic activity of 
neutrophils toward cancer cells in an EGFR-directed 
manner
Cancer cell surface-expressed CD47 was recently reported to 
act as an inhibitory signal for neutrophil-mediated trogocytosis 
and trogoptosis of cancer cells25 and as such may be implicated 
in reducing anticancer effector activity of IgG1-isotype thera-
peutic antibodies such as cetuximab (CTX). In this respect, 
bsAb CD47xEGFR-IgG1 showed potently enhanced neutro-
phil-mediated trogocytic uptake of DiD-labeled cell membrane 
fragments from parental FaDu cancer cells which could be 
detected in ~75% of neutrophils. In comparison, identical 
treatment of FaDu cells with CTX or an anti-EpCAM-IgG1 
antibody resulted in detection of FaDu cell-derived membrane 
fragments in only ~45% and ~10% of neutrophils, respectively 
(Figure 3c). Of note, when FaDu.CD47KO cancer cells were 
used instead, CTX and bsAb CD47xEGFR-IgG1 induced com-
parable neutrophil-mediated trogocytosis. As expected, IgG4- 
and IgG2s-isotype variants of bsAbs CD47xEGFR-IgG1 
showed reduced capacity to induce trogocytic uptake by neu-
trophils of cell membrane fragments from parental FaDu can-
cer cells (40% for IgG4 and 20% for IgG2s versus 75% for bsAb 
CD47xEGFR-IgG1, respectively (Figure 3d).
Of note, bsAb CD47xEGFR-IgG1 potentiated the trogocytic 
activity of neutrophils toward 6 out of 6 different EGFRpos/ 
CD47pos cancer cell types, whereas control bsAb CD47xMock- 
IgG1 showed only marginal capacity to do so (Figure 3d). BsAb 
CD47xEGFR-IgG1 did not enhance trogocytic activity of neu-
trophils toward EGFRneg/CD47pos cancer cell types (Figure 3e).
Collectively, this indicates that bsAb CD47xEGFR-IgG1 
potentiates the trogocytic activity of neutrophils toward 
CD47pos cancer cells in an EGFR-dependent manner.
bsAb CD47xEGFR-IgG1 promotes neutrophil-mediated 
trogoptosis of cancer cells
Recently, it was identified that CD47-SIRPα checkpoint block-
ade endows neutrophils to kill antibody-opsonized cancer cells 
via trogoptosis, a lytic form of trogocytosis which disrupts the 
integrity of the cancer cell membrane.25 In RTCA cell analysis, 
bsAb CD47xEGFR-IgG1 (and to a lesser extend the IgG4 iso-
type variant thereof), promoted neutrophil-mediated trogop-
tosis of EGFRpos/CD47pos cancer cells, as was evident from 
a prominent decrease in cell index within 2 h after addition 
of neutrophil effector cells (Figure 3f). Of note, in this assay 
treatment with bsAb CD47xEGFR-IgG2s did not promote 
neutrophil-mediated trogoptosis of cancer cells. However, 
when an Fc effector function-competent anti-EpCAM-IgG1 
antibody was combined with treatment with bsAb 
CD47xEGFR-IgG2s, neutrophil-mediated trogocytosis and 
trogoptosis was enhanced compared to treatment with anti- 
EpCAM-IgG1 antibody only, presumably due to its EGFR- 
directed CD47-blocking activity (Figure S3).
Taken together, these data demonstrate that bsAb 
CD47xEGFR-IgG1 selectively potentiates the trogocytic activ-
ity of neutrophils toward EGFRpos/CD47pos cancer cells result-
ing in the enhanced induction of trogoptotic cancer cell death.
bsAb CD47xEGFR-IgG1 promotes ADCP of EGFRpos/ 
CD47pos cancer cells in an EGFR-directed manner, 
independent of FcR interaction
BsAb CD47xEGFR-IgG1 markedly enhanced the ADCP activ-
ity of macrophages toward EGFR-transfected/CD47pos K562. 
EGFR cells compared to parental EGFRneg/CD47pos K562 cells 
ONCOIMMUNOLOGY 7
(Figure 4a,b). Similarly, bsAb CD47xEGFR-IgG1 selectively 
promoted macrophage-mediated ADCP activity toward var-
ious CD47pos cancer cell types with endogenous EGFR over-
expression (Figures 4c and S4). In contrast, bsAb CD47xMock- 
IgG1 showed no enhanced capacity to induce macrophage- 
mediated ADCP activity toward K562.EGFR cells. 
Interestingly, isotype variants of bsAb CD47xEGFR-IgG1 
with reduced (-IgG4) and no binding activity (-IgG2s) for 
human FcRs showed similar capacity to promote macrophage- 
mediated ADCP activity of EGFRpos/CD47pos cancer cells. This 
Figure 3. BsAb CD47xEGFR-IgG1 induces ADCC (a) ADCC reporter bioassay in which EGFRpos FaDu cells or EGFRneg A375m cells were coincubated with Jurkat. FcγRIIIa- 
NFAT-luc cells in the presence of bsAb CD47xEGFR-IgG1, CD47xEGFR-IgG2s, CD47xEGFR-IgG4, or CD47xMock-IgG1 (0.1 µg/ml). Luciferase activity (RLU) was measured 
after 6 h. (b) Evaluation of bsAb CD47xEGFR-IgG1 and bsAb CD47xEGFR-IgG2s for their respective capacity to engage ADCC activity of freshly isolated PBMCs from 5 
healthy volunteers toward A431 cancer cells endogenously expressing EGFR and CD47. PBMCs were cocultured with DiD-labeled A431 cancer cells at an E:T cell ratio of 
5:1 for 24 h in the presence (or absence) of bsAb CD47xEGFR-IgG1 or CD47xEGFRIgG2s (2 μg/ml each). Induction of apoptotic cancer cell death (annexin Vpos/PIpos) was 
assessed by flow cytometry. BsAb CD47xEGFR-IgG1 induces neutrophil-mediated trogocytosis and trogoptosis toward CD47posEGFRpos cancer cells. (c) FaDu or FaDu. 
CD47KO cells were DiD-labeled and incubated with neutrophils at an E:T cell ratio of 1:1 in the presence of anti-EpCAM-IgG1 (2 µg/ml), CTX or CD47xEGFR-IgG1 (both 
1 µg/ml). Trogocytosis was quantified as the percentage of DiDpos neutrophils by flow cytometry after 2 h. (d) Similar as in (b), trogocytosis was measured after DiD- 
labeled FaDu cells were incubated with neutrophils (E:T cell ratio of 1:1) in the presence of increasing concentrations (0.01–1 µg/ml) of bsAb CD47xEGFR-IgG1, 
CD47xEGFR-IgG2s or CD47xEGFR-IgG4. (e) Next, neutrophil-mediated trogocytosis of a panel of EGFRpos and EGFRneg DiD-labeled CD47-expressing cell lines was 
assessed in the presence of bsAb CD47xEGFR-IgG1 or CD47xMock-IgG1 (both 1 µg/ml). (f) xCELLigence real-time cytotoxicity assay shows neutrophil-induced 
trogoptosis of FaDu cells opsonized with bsAb CD47xEGFR-IgG1, -IgG2s, or -IgG4. After adhering, FaDu cells were coincubated with IFNγ-stimulated neutrophils (E:T 
cell ratio of 10:1) in the presence of indicated antibodies (2 µg/ml). Cell index was normalized prior to addition of neutrophils and antibodies. All graphs represent mean 
± SD. Graphs (c–e) represent data of three independent experiments with neutrophils from three different donors. Error bars in F indicate SD of quadruplicates. 
Statistical analysis in C was performed using one-way ANOVA followed by a Tukey post-hoc test (*p < .05, **p < .01, ***p < .001, ****p < .0001, ns not significant).
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indicates that, at least in this model system, bsAb CD47xEGFR- 
IgG1 promotes macrophage-mediated ADCP activity toward 
EGFRpos/CD47pos cancer that is independent of FcR 
interactions.
bsAb CD47xEGFR-IgG1-mediated ADCP promotes 
cross-presentation dependent on FcR interaction
BsAb CD47xEGFR-IgG1 was evaluated for its capacity to pro-
mote cross-presentation of cancer cell-derived peptides by 
macrophages to antigen-experienced CD8pos T cells. To this 
end, HLA-I-negative K562.EGFR.pp65 cells (ectopically 
expressing EGFR and CMVpp65) were treated with bsAb 
CD47xEGFR-IgG1 to induce macrophage-mediated ADCP 
activity. Subsequently, these macrophages were assessed for 
enhanced cross-presentation of CMVpp65-derived peptides 
to HLA-B7*07:02-matched CMVpp65-specific CD8+ T cells. 
Indeed, enhanced cross-presentation by these macrophages 
was evident from upregulation of CD137 and enhanced secre-
tion of IFNγ by the CD8pos T cells (Figure 4d,e). The upregula-
tion of CD137 and secretion of IFNγ were strongly inhibited 
when this experiment was performed in the presence of an 
excess amount of an HLA ABC-blocking antibody (Figure 4f, 
g). Of note, in the above setting IgG4 and IgG2s isotype 
variants of bsAb CD47xEGFR-IgG1 showed only marginally 
enhanced capacity to promote cross-presentation. This indi-
cates that bsAb CD47xEGFR-IgG1 promotes cross- 
presentation in an FcR-dependent manner.
Discussion
The clinical efficacy of current monospecific CD47-blocking 
antibodies is potentially hampered by 'on-target/off- 
tumor' binding to a vast majority of normal cells that also 
expresses CD47.26 The lack of tumor-selectivity of conven-
tional CD47-blocking antibodies may preclude their sufficient 
accretion at the tumor site(s).10–13 Moreover, blockade of 
CD47 on normal cells may contribute to the induction of 
autoimmune-related adverse events.
To address these issues, we developed a bsAb-based 
approach to more selectively direct CD47 blockade to cancer 
cells. For this purpose, we selected EGFR to serve as target 
antigen of our CD47-blocking bsAb approach. EGFR is a well- 
established cell surface target antigen with oncogenic signaling 
capacity that is overexpressed and/or mutated in various 
malignancies.14–16 Our data demonstrate that the capacity of 
bsAb CD47xEGFR to simultaneously bind to CD47 and EGFR 
resulted in a significantly enhanced overall binding strength 
(avidity) for EGFRpos/CD47pos cancer cells. Importantly, this 
binding induced rapid cointernalization of antibody-antigen 
Figure 4. BsAb CD47xEGFR-IgG1-mediated phagocytosis of cancer cells by macrophages facilitates cross-presentation of peptides in MHC-I and subsequent activation of 
antigen-specific CD8+ T cells. Phagocytosis of GFP-labeled (a) K562, (b) K562.EGFR cells, or (c) CFSE-labeled NCI-H292 cells by M1 macrophages (E:T cell ratio of 1:2) in the 
presence of different isotypes of bsAb CD47xEGFR or control antibodies (1 µg/ml) after 3 h. (d) K562.EGFR cells or K562.EGFR.pp65 cells were coincubated with M1 
macrophages from a CMV-seropositive donor (E:T cell ratio = 1:2) in the presence of CD47xEGFR-IgG1 or control antibodies (1 µg/ml) for 3 h. K562 cells and unbound 
antibody were washed away prior to addition of a priori expanded CMVpp65-specific autologous CD8+ T cells (E:T cell ratio of 1:1). After 24 h, the percentage of 
CD137pos T cells within CD8+ T cell population was measured by flow cytometry. (e) IFNγ levels in culture supernatant of D were measured by ELISA. (f) As in D, but HLA- 
ABC blocking antibody W6/32 (10 µg/ml) was added after addition of CMVpp65-specific autologous CD8+ T cells to block cross-presentation capacity of macrophages. 
(g) IFNγ levels in culture supernatant of F were measured by ELISA. Graphs (a–c) represent mean ± SD of independent experiments using at least three different donors. 
Statistical analysis in (a–c) were performed using One-way ANOVA followed by a Tukey post-hoc test. Graphs (d–g) represent independent experiments with 
macrophages from the same CMV-seropositive HLA-B7*07:02-matched donor (*p < .05, **p < .01, ***p < .001, ****p < .0001, ns not significant).
ONCOIMMUNOLOGY 9
complexes which resulted in prolonged displacement of both 
EGFR and CD47 from the cancer cell surface. This unique 
feature may explain the potent capacity of bsAb CD47xEGFR 
to selectively inhibit the proliferation of EGFRpos/CD47pos 
cancer cells. Although not studied here, concurrent inhibition 
of EGFR- and CD47-associated oncogenic signaling events by 
bsAb CD47xEGFR may also mediate other mutually reinfor-
cing anticancer effects.
ADCC is an important effector mechanism of therapeutic 
antibodies to destroy cancer cells and can be mediated by 
various Fc-receptor-expressing myeloid immune effector 
cells, in particular by neutrophils. Recently, the mode-of- 
action by which neutrophils kill antibody-opsonized cancer 
was shown to involve trogoptosis, an alternate lytic form of 
ADCC that mechanically disrupts the cancer cell membrane.25 
Intriguingly, it was demonstrated that neutrophil-ADCC of 
trastuzumab-opsonized breast cancer cells was potentiated 
upon cotreatment with a CD47-blocking antibody or a SIRPα- 
blocking antibody.9,25 Giving the combined capacities of bsAb 
CD47xEGFR-IgG1 to bind and block CD47/EGFR with 
enhanced avidity and to induce ADCC via its IgG1 Fc domain, 
we evaluated whether this bsAb enhanced the trogocytic activ-
ity of neutrophils in a single agent setting. Indeed, opsonization 
of EGFRpos/CD47pos cancer cells with bsAb CD47xEGFR- 
IgG1, but not its IgG4 or IgG2s isotype variants, markedly 
enhanced neutrophil-mediated trogocytosis resulting in rapid 
and selective trogoptosis of these cancer cells.
It is well established that interaction of IgG/antigen- 
complexes with Fc-γ receptors on phagocytes promotes shut-
tling of exogenous antigen into the cross-presentation path-
way, thereby priming adoptive CD8pos T cell-mediated 
anticancer immunity (reviewed in27). In this respect, it is 
noteworthy that bsAb CD47xEGFR-IgG1 is equipped with 
a fully functional IgG1 Fc effector domain. Indeed, our results 
demonstrated that opsonization of CMVpp65-expressing 
EGFRpos/CD47pos cancer cells with bsAb CD47xEGFR-IgG1 
promoted antigen cross-presentation by macrophages which 
was evident from their enhanced capacity to activate HLA- 
matched pp65-specific CD8pos T cells. Importantly, isotype 
variants IgG4 or IgG2s of bsAb CD47xEGFR-IgG1 only poorly 
induced cross-presentation.
Typically, therapeutic CD47-blocking antibodies are 
equipped with engineered human Fc domains with reduced or 
fully silenced ADCC/ADCP activity to avoid elimination of 
CD47-expressing normal cells.28 In the current study, we com-
pared bsAb CD47xEGFR IgG1, IgG4 and IgG2s isotypes for 
their ability to induce neutrophil-mediated trogocytosis and 
trogoptosis, ADCC signaling and macrophage mediated cross- 
presentation. From this evaluation it became clear that only the 
bsAb CD47xEGFR-IgG1 isotype has potent activity in all these 
assays. Therefore, clinical CD47 antibodies equipped with (par-
tially) silenced human Fc domains will have limited capacity to 
promote neutrophil-mediated trogoptosis, ADCC and APC- 
mediated cross-presentation of tumor antigens. This trade-off 
to reduce toxicity of clinical CD47-blocking antibodies toward 
normal cells may therefore come with a markedly reduced anti- 
cancer activity. However, recent clinical trials demonstrated that 
the efficacy of such Fc-silenced CD47-blocking antibodies can 
be enhanced when treatment was combined with an Fc effector- 
competent anticancer antibody.10 Although it is clear that more 
in-depth toxicity studies for bsAb CD47xEGFR-IgG1 are 
needed to evaluate potential toxicity toward normal cells, 
bsAb CD47xEGFR-IgG1 could represent a two-in-one antibody 
approach in which the CD47-blocking activity is selectively 
directed to EGFRpos cancer cell types. We uncovered that the 
combination of bsAb CD47xEGFR-IgG2s with an anti-EpCAM 
-IgG1 antibody potently enhanced neutrophil-mediated trogo-
cytosis and trogoptosis compared to treatment with anti- 
EpCAM-IgG1 antibody only. Therefore, an alternative thera-
peutic approach could be to combine treatment of cancer cells 
with bsAb CD47xEGFR-IgG4 or -IgG2s with a therapeutic anti-
body equipped with a fully functional IgG1 Fc domain directed 
at an alternate tumor-associated antigen coexpressed at the 
cancer cell surface.
Obviously, a more detailed fit-for-purpose evaluation of 
bsAb CD47xEGFR-IgG1 should be evaluated in vivo in 
a realistic and informative animal model. In particular, 
a patient-derived xenograft (PDX) model using EGFR- 
transgenic/immune humanized NSG mice appears to be useful 
for such purpose. However, the results from such studies in 
mice should be interpreted with caution since there is a 10-fold 
higher binding affinity between human CD47 and mutant 
SIRPα known to be expressed in NOD mice29,30. 
Consequently, the high affinity interaction of human CD47 
with murine mutant SIRPα may result in an unrealistic strong 
inhibition of phagocytosis in murine myeloid effector cells. 
Moreover, in such a PDX model, only the engrafted tumor 
and immune cells express human CD47, which does not fully 
recapitulate the massive CD47 “antigen sink” present in 
humans. The use of non-NOD syngeneic immunocompetent 
tumor models or human SIRPα transgenic Rag2nullIl2rγnull 
mice could allow for better evaluation of CD47-blocking 
antibodies.31,32 Clearly, the development of an animal model 
that tackles these and other issues related with the in vivo 
evaluation of bsAb CD47xEGFR-IgG1 are beyond the scope 
of our current report.
Recently, it was reported that treatment with EGFR tyrosine 
kinase inhibitor (TKI) gefitinib induced a marked down- 
regulation of CD47 expression by responsive NSCLC cells. 
Importantly, upon acquisition of gefitinib resistance this response 
was reverted, as was evident from a marked up-regulation of 
CD47 expression by EGFR TKI nonresponsive cancer cells. 
However, this selective overexpression of CD47 renders EGFR- 
mutant NSCLC cells more sensitive to the phagocytic clearance 
induced by CD47-blocking antibodies.33 In this respect, bsAb 
CD47xEGFR-IgG1 may provide a promising immunotherapeu-
tic option for naïve and TKI-resistant EGFR-mutant NSCLC.
In conclusion, our data demonstrate that bsAb 
CD47xEGFR-IgG1 has multiple and possibly mutually reinfor-
cing anticancer activities that are not available in any of the 
current conventional CD47-blocking antibodies. In particular, 
bsAb CD47xEGFR-IgG1 as ability to: (1) simultaneously bind 
to both EGFR and CD47 resulting in enhanced avidity toward 
EGFRpos/CD47pos cancer cells; (2) block oncogenic signaling 
by EGFR and possibly those mediated by CD47; (3) block 
CD47/SIRPα interaction in an EGFR-directed manner; (4) 
promote cointernalization and prolonged cell surface- 
displacement of both EGFR and CD47 from cancer cells; (5) 
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enhance EGFR-directed neutrophil-mediated trogocytosis and 
trogoptosis of cancer cells as a single agent; (6) enhance EGFR- 
directed phagocytosis of cancer cells; and (7) promote cross- 
presentation antigens derived from EGFRpos/CD47pos cancer 
cells to engage the adaptive immune system.
Taken together, bsAb CD47xEGFR-IgG1 may represent 
novel antibody-based strategy for enhancing selectivity and 
therapeutic efficacy of CD47-SIRPα checkpoint inhibition 
approaches in EGFR-overexpressing malignancies.
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